Utility of prostate specific antigen density and free to total prostate specific antigen ratio for detecting prostate cancer in Iranian men: A prospective study of 187 cases

Current Urology

Volumn 4, Issue 1, 2010, Pages 1-5

  Dadkhah, Farid ^a   Safarinejad, Mohammad R ^b   Amini, Erfan ^a   Lashay, Ali R ^a   Baghayee, Arash ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Predictive value of tests; Prostate adenocarcinoma; Prostate specific antigen; Prostatic neoplasms; Receiver operation characteristic curve; Sensitivity; Specificity

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; HUMAN; IRAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; TRANSRECTAL ULTRASONOGRAPHY;

EID: 77953387684     PISSN: 16617649     EISSN: 16617657     Source Type: Journal    
DOI: 10.1159/000253399     Document Type: Article

References (27)

1. Howe HL, Wingo PA, Thun MJ, Ries LA, Rosenberg HM, Feigal EG, Edwards BK: Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. J Natl Cancer Inst 2001;93:824-842.
2. Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, Richie JP, deKernion JB, Walsh PC, Scardino PT, Lange PH, Subong EN, Parson RE, Gasior GH, Loveland KG, Southwick PC: Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998;279:1542-1547.
3. Roobol MJ, Zappa M, Määttänen L, Ciatto S: The value of different screening tests in predicting prostate biopsy outcome in screening for prostate cancer data from a multicenter study (ERSPC). Prostate 2007;67:439-446.
4. Benson MC, Whang IS, Pantuck A, Ring K, Kaplan SA, Olsson CA, Cooner WH: Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol 1992;147:815-816.
5. Stenman UH, Hakama M, Knekt P, Aromaa A, Teppo L, Leinonen J: Serum concentrations of prostate specific antigen and its complex with alpha 1-antichymotrypsin before diagnosis of prostate cancer. Lancet 1994;344:1594-1598.
6. Carter HB, Pearson JD, Metter EJ, Brant LJ, Chan DW, Andres R, Fozard JL, Walsh PC: Longitudinal evaluation of prostate specific antigen levels in men with and without prostate disease. JAMA 1992;267:2215-2220.
7. Zlotta AR, Djavan B, Marberger M, Schulman CC: Prostate specific antigen of the transition zone: a new parameter for prostate cancer prediction. J Urol 1997;157:1315-1321.
8. Kang SH, Bae JH, Park HS, Yoon DK, Moon DG, Kim JJ, Cheon J: Prostate-specific antigen adjusted for the transition zone volume as a second screening test: a prospective study of 248 cases. Int J Urol 2006;13:910-914.
9. Yamamoto S, Kin U, Nakamura K, Hamano M, Nishikawa Y, Takenouchi T, Maruoka M: Transperineal ultrasoundguided 12-core systematic biopsy of the prostate for patients with a prostate specific antigen level of 2.5-20 ng/ml in Japan. Int J Clin Oncol 2005;10:117-121.
10. Okihara K, Kitamura K, Okada K, Mikami K, Ukimura O, Miki T: Ten year trend in prostate cancer screening with high prostate-specific antigen exposure rate in Japan. Int J Urol 2008;15:156-160.
11. Sheikh M, Al-Saeed O, Kehinde EO, Sinan T, Anim JT, Ali Y: Utility of volume adjusted prostate specific antigen density in the diagnosis of prostate cancer in Arab men. Int Urol Nephrol 2005;37:721-726.
12. Zheng XY, Xie LP, Wang YY, Ding W, Yang K, Shen HF, Qin J, Bai Y, Chen ZD: The use of prostate specific antigen (PSA) density in detecting prostate cancer in Chinese men with PSA levels of 4-10 ng/mL. J Cancer Res Clin Oncol 2008;134:1207-1210.
13. Stephan C, Stroebel G, Heinau M, Lenz A, Roemer A, Lein M, Schnorr D, Loening SA, Jung K: The ratio of prostate-specific antigen (PSA) to prostate volume (PSA density) as a parameter to improve the detection of prostate carcinoma in PSA values in the range of < 4 ng/mL. Cancer 2005;104:993-1003.
14. Sakai I, Harada K, Hara I, Eto H, Miyake H: Limited usefulness of the free-to-total prostate specific antigen ratio for the diagnosis and staging of prostate cancer in Japanese men. Int J Clin Oncol 2004;9:64-67.
15. Aslan G, Irer B, Kefi A, Celebi I, Yörükoǧlu K, Esen A: The value of PSA, free-to-total PSA ratio and PSA density in the prediction of pathologic stage for clinically localized prostate cancer. Int Urol Nephrol 2005;37:511-514.
16. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E: Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987;317:909-916.
17. Kehinde EO, Sheikh M, Mojimoniyi OA, Francis I, Anim JT, Nkansa-Dwamena D, Al-Awadi KA: High serum prostate specific antigen levels in the absence of prostate cancer in Middle eastern men: the clinicians dilemma. BJU Int 2000:91:618-622.
18. Hosseini SY, Moharramzadeh M, Ghadian AR, Hooshyar H, Lashay AR, Safarinejad MR: Population-based screening for prostate cancer by measuring total serum prostate-specific antigen in Iran. Int J Urol 2007;14:406-411.
19. Safarinejad MR: Population-based screening for prostate cancer by measuring free and total serum prostate-specific antigen in Iran. Ann Oncol 2006;17:1166-1171.
20. Bazinet M, Meshref AW, Trudel C, Aronson S, Péloquin F, Nachabe M, Bégin LR, Elhilali MM: Prospective evaluation of prostate-specific antigen density and systematic biopsies for early detection of prostatic carcinoma. Urology 1994;43:44-51.
21. Rommel FM, Agusta VE, Breslin JA, Huffnagle HW, Pohl CE, Sieber PR, Stahl CA: The use of prostate specific antigen and prostate specific antigen density in the diagnosis of prostate cancer in a community based urology practice. J Urol 1994;151:88-93.
22. Seaman E, Whang M, Olsson CA, Katz A, Cooner WH, Benson MC: PSA density (PSAD). Role in patient evaluation and management. Urol Clin North Am 1993;20:653-663.
23. Lam JS, Cheung YK, Benson MC, Goluboff ET: Comparison of the predictive accuracy of serum prostate specific antigen levels and prostate specific antigen density in the detection of prostate cancer in Hispanic-American and white men. J Urol 2003;170:451-456.
24. Kuriyama M, Uno H, Watanabe H, Yamanaka H, Saito Y, Shida K: Determination of reference values for total PSA, F/T and PSAD according to prostatic volume in Japanese prostate cancer patients with slightly elevated serum PSA levels. Jpn J Clin Oncol 1999;29:617-622.
25. Catalona WJ, Southwick PC, Slawin KM, Partin AW, Brawer MK, Flanigan RC, Patel A, Richie JP, Walsh PC, Scardino PT, Lange PH, Gasior GH, Loveland KG, Bray KR: Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. Urology 2000;56:255-260.
26. Ozdal OL, Aprikian AG, Begin LR, Behlouli H, Tanguay S: Comparative evaluation of various prostate specific antigen ratios for the early detection of prostate cancer. BJU Int 2004;93:970-974.
27. Djavan B, Zlotta A, Kratzik C, Remzi M, Seitz C, Schulman CC, Marberger M: PSA, PSA density, PSA density of transition zone, free/total PSA ratio, and PSA velocity for early detection of prostate cancer in men with serum PSA 2.5 to 4.0 ng/ml. Urology 1999;54:517-522.